683 results on '"Ritter, Gerd"'
Search Results
2. Defining the Critical Hurdles in Cancer Immunotherapy
3. Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes and a High $CD8^+/regulatory$ T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer
4. IFN-γ Enables Cross-Presentation of Exogenous Protein Antigen in Human Langerhans Cells by Potentiating Maturation
5. Recombinant NY-ESO-1 Protein with ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses in Humans
6. Survey of Naturally Occurring CD4 + T Cell Responses against NY-ESO-1 in Cancer Patients: Correlation with Antibody Responses
7. A Monoclonal Antibody Recognizing Human Cancers with Amplification/Overexpression of the Human Epidermal Growth Factor Receptor
8. Process development for production and purification of the Schistosoma mansoni Sm14 antigen
9. CD8 + T Cell Responses against a Dominant Cryptic HLA-A2 Epitope after NY-ESO-1 Peptide Immunization of Cancer Patients
10. Differential Presentation of a Soluble Exogenous Tumor Antigen, NY-ESO-1, by Distinct Human Dendritic Cell Populations
11. Induction of Primary NY-ESO-1 Immunity: CD8+ T Lymphocyte and Antibody Responses in Peptide-Vaccinated Patients with NY-ESO-1+ Cancers
12. Strategy for Monitoring T Cell Responses to NY-ESO-1 in Patients with Any HLA Class I Allele
13. Monitoring CD8 T Cell Responses to NY-ESO-1: Correlation of Humoral and Cellular Immune Responses
14. The Human A33 Antigen is a Transmembrane Glycoprotein and a Novel Member of the Immunoglobulin Superfamily
15. Supplementary Figure 1 from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
16. Supplementary Figure 2 from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
17. Data from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
18. Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
19. Supplementary Figure Legend from Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
20. Supplementary Table 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
21. Supplementary Figure Legends from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
22. Supplementary Figure 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
23. Supplementary Figure 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
24. Supplementary Table 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
25. Supplementary Data from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
26. Supplementary Figure 1 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
27. Supplementary Figure 5 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
28. Supplementary Table 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
29. Supplementary Figure 4 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
30. Supplementary Figure Legends from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
31. Conflict of Interest from NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
32. Supplementary Figure 4 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
33. Supplementary Table 2 from Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer
34. Data from Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients
35. Supplementary Figure 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
36. Supplementary Figure Legend from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
37. Supplementary Figure 3 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
38. Supplementary Figure 2 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
39. Supplementary Table 3 from Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer
40. Supplementary Table 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
41. Supplementary Methods and Figure Legend from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
42. Supplementary Figure 1 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein
43. Supplementary Data from Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients
44. Supplementary Table 1 from Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer
45. Supplementary Figure 3 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
46. Supplementary Figure 2 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity
47. Supplementary Figure 3 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
48. Supplementary Figure 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
49. Data from Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
50. Supplementary Figures 1-3 from Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.